Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower failed extubation compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower a) Cerebral palsy or gross motor disability compared with placebo or control (moderate certainty).
Methylxanthine showed no clear difference in b) Developmental delay at 18 to 24 months compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower any apneic episodes compared with placebo or control (moderate certainty).
Methylxanthine probably leads to lower failed apnea reduction compared with placebo or control (moderate certainty).
Methylxanthine may leads to lower positive‐pressure ventilation after institution of treatment compared with placebo or control (low certainty).
Methylxanthine leads to lower supplemental oxygen at 36 weeks' postmenstrual age compared with placebo or control (high certainty).
Fetal biometry showed no clear difference in caesarean delivery compared with maternal glycaemic values (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether fetal biometry changes hypertensive disorders of pregnancy (including pre‐eclampsia,… compared with maternal glycaemic values (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether fetal biometry changes large‐for‐gestational age compared with maternal glycaemic values (very low certainty).
It is very uncertain whether fetal biometry changes shoulder dystocia compared with maternal glycaemic values (very low certainty).
It is very uncertain whether fetal biometry changes composite outcome neonatal morbidity or mortality compared with maternal glycaemic values (very low certainty).
Fetal biometry showed no clear difference in neonatal hypoglycaemia compared with maternal glycaemic values (low certainty).
It is very uncertain whether fetal biometry changes perinatal mortality compared with maternal glycaemic values (very low certainty).